Evidence map›Paper›PMID 40852677›Full record

ArticleAnnals of Ibadan postgraduate medicine2025

COVID-19 TESTING PERFORMANCE AND STRATEGIES FOR RAPID SCALE UP OF LABORATORY CAPACITY IN A PUBLIC HEALTH EMERGENCY IN A RESOURCE-CONSTRAINED SETTING: THE SARS-COV-2 NIGERIA RESPONSE EXPERIENCEJ.

S Bello, A S Adebowale, M D Dairo, E A Bamgboye, M M Salawu, R F Afolabi, A Namale, S Kizito, S N Kabwama, R Ndejjo and 3 more

Abstract read
In one paragraph

Article in Annals of Ibadan postgraduate medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

S BelloFaculty of Public Health, College of Medicine, University of Ibadan, Nigeria.
A S AdebowaleFaculty of Public Health, College of Medicine, University of Ibadan, Nigeria.
M D DairoFaculty of Public Health, College of Medicine, University of Ibadan, Nigeria.
E A BamgboyeFaculty of Public Health, College of Medicine, University of Ibadan, Nigeria.
M M SalawuFaculty of Public Health, College of Medicine, University of Ibadan, Nigeria.
R F AfolabiFaculty of Public Health, College of Medicine, University of Ibadan, Nigeria.
A NamaleMakerere University School of Public Health, Uganda.
S KizitoMakerere University School of Public Health, Uganda.
S N KabwamaMakerere University School of Public Health, Uganda.
R NdejjoMakerere University School of Public Health, Uganda.
S KiwanukaMakerere University School of Public Health, Uganda.
R WanyenzeMakerere University School of Public Health, Uganda.
O I FawoleFaculty of Public Health, College of Medicine, University of Ibadan, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sufficient laboratory capacity is vital to containing infectious diseases outbreaks. This study was conducted to document the strategies adopted to scale up laboratory testing capacity during Nigeria's response to COVID-19 pandemic. Methods: This cross-sectional descriptive study adopted a mixed method approach including desk reviews and key informant interviews (KIIs). The KIIs were conducted among actors of the COVID-19 response teams in states and federal ministries of health in Nigeria. Results: At the beginning of the pandemic in Nigeria, testing performance was poor, but this improved over time. To manage the demand for testing, Nigeria adopted targeted testing with a focus on symptomatic contacts,alerts, and returning travelers from high-risk countries who were symptomatic during the quarantine period.. Strategies to enhance laboratory capacity and improve the turnaround time for results included leveraging on existing tuberculosis laboratory networks or building new laboratories where none existed; decentralization of sample collection and testing; staff health workers repurposing and hiring of volunteers; training and retraining of laboratory personnel; adoption of rapid diagnostic testing; and strengthening public-private partnerships. From an initial three laboratories with capacity to test for SARSCoV- 2 in February, 2020, the number of laboratories increased to 158 by March, 2022. Although laboratory capacity increased, logistics and supply chain disruption were still a challenge. Conclusion: Investment in local manufacturing capacities of laboratory consumables such as RDTs and reagents would promote self-reliance and sustainability for a country as populous as Nigeria.

Indexed as

COVID-19 pandemiceLaboratory capacityPublic health emergenciesResource'constrained settingsThe global health security agenda

Identifiers

PMID40852677
PMCPMC12337959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.